^
Association details:
| Biomarker: | PD-L1 elevation |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy
Published date:
12/10/2020
Excerpt:
Within the ctDNA+ pts, additional survival benefit was derived for PD-L1-high pts (HR=0.52 [95% CI 0.331-0.82]; p=0.004), and TMB-high pts (HR=0.34 [95% CI 0.19-0.6]; p<0.0001])….Post-surgical ctDNA positivity, associated with high risk for recurrence and death, identified MIUC patients likely to benefit from adjuvant atezo.
DOI:
10.1016/annonc/annonc389
Trial ID:
